MedTrace Logo

Registry Of Best Up-titration STrategies in Acute Heart Failure

NCT05865665 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2023-05-19

No results posted yet for this study

Summary

STRONG-HF showed that rapid up-titration of renin-angiotensin inhibitor (RASI), beta-blocker, and mineralocorticoid receptor antagonist (MRA) to full optimal doses within 2 weeks post-discharge from a hospital admission for acute heart failure (AHF), using frequent safety assessments, significantly reduced the 180-day risk of HF readmission or death and significantly increased 90-day quality of life regardless of left ventricular ejection fraction (LVEF). Recent evidence also suggests that initiation of angiotensin-receptor neprilysin inhibitor (ARNI) and SGLT-2 inhibitors close to the time of discharge regardless of LVEF, and iron supplementation where indicated, improve patient prognosis.

In this prospective registry of patients not treated with optimal doses of oral HF medications being discharged from an admission for AHF, ROBUST-HF, data will be collected describing their post-discharge care including the management of their oral HF medications and frequency and content of post-discharge assessments and clinical outcomes through 6 months post discharge.

Conditions

  • Acute Heart Failure

Sponsors & Collaborators

  • INSERM UMR-942, Paris, France

    collaborator OTHER

  • Hôpitaux Universitaires Saint-Louis-Lariboisière

    collaborator UNKNOWN

  • Momentum Research, Inc.

    collaborator INDUSTRY

  • Roche Diagnostics GmbH

    collaborator INDUSTRY

  • Heart Initiative

    lead OTHER

Principal Investigators

  • Alexandre Mebazaa, MD · Hôpitaux Universitaires Saint-Louis-Lariboisière, University Paris Diderot, Inserm 942

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2027-12-31
Completion
2027-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05865665 on ClinicalTrials.gov